Coherus Oncology, Inc. (CHRS) › Capital ExpendituresCoherus Oncology, Inc. (CHRS) — Capital ExpendituresAnnual figures by period end, from SEC filings.2012-12-31: $1.78M2013-12-31: $373.0K2014-12-31: $2.85M2015-12-31: $6.16M2016-12-31: $6.51M2017-12-31: $4.57M2018-12-31: $789.0K2019-12-31: $1.82M2020-12-31: $7.23M2021-12-31: $1.29M2022-12-31: $2.04M2023-12-31: $286.0K$286.0K2012-12-31Capital Expenditures (USD)2023-12-31Period endedCapital ExpendituresChange YoYSource filing2023-12-31$286.0K-86.0%2024-03-15From 2023-01-012022-12-31$2.04M+58.2%2024-03-15From 2022-01-012021-12-31$1.29M-82.2%2024-03-15From 2021-01-012020-12-31$7.23M+296.9%2023-03-06From 2020-01-012019-12-31$1.82M+130.9%2022-02-23From 2019-01-012018-12-31$789.0K-82.7%2021-02-25From 2018-01-012017-12-31$4.57M-29.8%2020-02-27From 2017-01-012016-12-31$6.51M+5.7%2019-02-28From 2016-01-012015-12-31$6.16M+116.4%2018-03-08From 2015-01-012014-12-31$2.85M+663.8%2017-03-14From 2014-01-012013-12-31$373.0K-79.1%2016-02-29From 2013-01-012012-12-31$1.78M—2015-03-23From 2012-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)